Management of patients with T2D and NAFLD: the role of PPAR-γ
Sign in to receive more information about videos like this
In this very comprehensive video, Prof. Kenneth Cusi, USA, reviews the guidelines on NAFLD that are currently being updated. He also shares highlights on the rationale of PPARs in NASH and discusses the clinical trials with Pioglitazone. He addresses the positive results as well as the misconceptions and barriers for using PPAR-γ in NASH.
This content is restricted to site members. If you are an existing user, please log in. New users may register below.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.